End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | +0.69% | -13.17% | -47.27% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | - | - | 60.19 |
Enterprise Value (EV) 1 | - | - | 80.09 |
P/E ratio | -5.94 x | -5.79 x | -0.51 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | -2.81 x |
EV / FCF | - | - | 7,077,483 x |
FCF Yield | - | - | 0% |
Price to Book | -3.63 x | 207 x | -1.03 x |
Nbr of stocks (in thousands) | - | - | 21,889 |
Reference price 2 | 9.690 | 9.950 | 2.750 |
Announcement Date | 04/08/23 | 04/08/23 | 16/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 0.426 | 0.077 | - |
EBITDA 1 | -20.73 | -23.14 | -28.54 |
EBIT 1 | -21.86 | -24.35 | -29.75 |
Operating Margin | -5,131.69% | -31,618.18% | - |
Earnings before Tax (EBT) 1 | -23.26 | -26.75 | -82.95 |
Net income 1 | -23.26 | -26.75 | -82.95 |
Net margin | -5,461.27% | -34,745.45% | - |
EPS 2 | -1.633 | -1.719 | -5.377 |
Free Cash Flow | - | -16.5 | 11.32 |
FCF margin | - | -21,426.62% | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 04/08/23 | 04/08/23 | 16/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 51.6 | 11.9 | 19.9 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | -2.49 x | -0.5151 x | -0.697 x |
Free Cash Flow | - | -16.5 | 11.3 |
ROE (net income / shareholders' equity) | - | 147% | 290% |
ROA (Net income/ Total Assets) | - | -88.5% | -113% |
Assets 1 | - | 30.24 | 73.2 |
Book Value Per Share 2 | -2.670 | 0.0500 | -2.680 |
Cash Flow per Share 2 | 0.0200 | 0 | 0 |
Capex 1 | 0.4 | 0.1 | - |
Capex / Sales | 94.6% | 131.17% | - |
Announcement Date | 04/08/23 | 04/08/23 | 16/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-47.27% | 36.09M | |
+51.85% | 57.87B | |
+41.16% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- NKGN Stock
- Financials NKGen Biotech, Inc.